ArticleJournal of translational medicine2026
Mesenchymal Stem cell therapy with GHRH receptor analog resolves post-stroke vasogenic edema via modulating AQP4 and mitochondria-ER crosstalk.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundPost-stroke edema is one of the fatal consequences of ischemic stroke where increased intracranial pressure can exacerbate neurological dysfunction leading to mortality. To date, conventional post-stroke therapy has failed to manage cerebral edema and render neuroprotection. Earlier, our lab reported the benefits of intra-arterially administered mesenchymal stem cells (IA MSCs) in alleviating post-stroke vasogenic edema. Recently, post-stroke neuroendocrine regulation involving growth hormone releasing hormone receptor (GHRH-R) analog is gaining attention as one of the potential targets for stroke intervention, adjunctive to the existing conventional therapies. Therefore, the current study aims to explore the combined therapeutic potential of IA MSCs and GHRH-R analogs in resolution of cerebral vasogenic edema following ischemic stroke.
methodsMiddle cerebral artery occlusion (MCAo) method was used to induce focal ischemic stroke in male Sprague Dawley rats. Further rats were treated with 1 × 10
resultsPost-stroke administration of IA MSCs and MR-409 combination reduced mitochondria-endoplasmic reticulum (ER) distance, modulated AQP4 expression, leading to reduction in blood-brain-barrier (BBB) disruption in the short term along with resolving vasogenic edema in the long term.
conclusionThe study provides indirect preliminary evidence of combined administration of IA MSCs with sustained release GHRH-R agonist towards increasing the mitochondria-endoplasmic reticulum association, altering the expression of AQP4, maintaining BBB integrity and alleviating post-stroke vasogenic edema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.